Latest Breaking News On - Global clinical development at abraxis bioscience - Page 1 : comparemela.com

Share this article Share this article BEVERLY HILLS, Calif., April 26, 2021 /PRNewswire/ GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company s proprietary natural killer (NK) cell engager, TriKE™ protein biologic technology platform, today announced the appointment of Gregory Berk, M.D., to the position of Chief Medical Officer. Dr. Berk has served as a Director on GT Biopharma s Board since November 2020, and resigns that post in conjunction with his appointment. The Company is also pleased to announce that Jeffrey S. Miller, M.D., who has supported GT Biopharma as the Company s Consulting Chief Medical Officer since August 2019, will become the Company s Consulting Chief Scientific Officer. Dr. Miller, with his colleagues at the University of Minnesota, is the inventor of the novel TriKE™ technology platform. Dr. Miller will continue his leadership role with respect to the design a

Julie-seidel
Jeff-miller
Gregory-berk
Susan-roush
Jeffreys-miller
Anthonyj-cataldo
David-castaneda
Beverly-hills
Prnewswire-gt-biopharma-inc
Board-member-of-sideris-pharmaceuticals
Global-clinical-development-at-abraxis-bioscience